Accelerating Advancement In Gene Therapy By Improving Downstream Purification Of Viral Vectors

By Orjana Terova, John Li, Jessica de Rooij, Pim Hermans, Alejandro Becerra and Frank Detmers; Thermo Fisher Scientific

Over the past decade, gene therapy applications and their importance in the biopharmaceutical industry have been increasing. The non-pathogenic adeno-associated virus (AAV) has emerged as the vector of choice for many therapies but purification of biologically active viral vectors for large-scale commercial use is a challenge. Thermo Fisher Scientific has developed  downstream purification solutions, enabling the scale-up of viral vector production.


  • Multiple chromatography steps & concentration needed due to challenging feedstock
  • Long process development lead times
  • Cumulative yield losses with each unit operation
access the Poster!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online